Aquestive Therapeutics reported a significant revenue decline in the third quarter of 2026, largely attributed to the timing of manufacturing orders for Suboxone. Despite the financial miss, the company achieved a critical milestone with the FDA's acceptance of the Anaphylm NDA resubmission, shifting investor focus toward its 2027 commercialization catalysts.
Key Highlights
- Revenue of $7.6 million fell sharply below the $15.42 million estimate due to a 41% year-over-year decline in manufacturing and supply fluctuations.
- The FDA assigned a PDUFA goal date of March 16, 2027, for Anaphylm, which would be the first oral rescue medication for severe allergic reactions if approved.
- Strategic liquidity was bolstered by an out-licensing agreement for Libervant with Eton Pharmaceuticals, providing a $10 million upfront payment in October 2026.